Korro Bio, Inc. (KRRO)
(Real Time Quote from BATS)
$41.11 USD
-0.32 (-0.77%)
Updated Sep 16, 2024 03:02 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Korro Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 14 | 37 | 29 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 14 | 37 | 29 |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 83 | 98 | 65 | 50 |
Income After Depreciation & Amortization | -85 | -83 | -84 | -28 | -21 |
Non-Operating Income | 3 | 2 | 0 | 1 | 2 |
Interest Expense | 0 | 1 | 1 | 0 | 0 |
Pretax Income | -81 | -82 | -85 | -26 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -81 | -82 | -85 | -27 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -81 | -82 | -85 | -27 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -81 | -80 | -81 | -26 | -20 |
Depreciation & Amortization (Cash Flow) | 4 | 3 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -85 | -83 | -84 | -28 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.53 | 0.70 | 0.69 | 0.65 | 0.17 |
Diluted EPS Before Non-Recurring Items | -53.08 | -116.50 | -123.50 | -41.00 | -114.50 |
Diluted Net EPS (GAAP) | -53.08 | -116.50 | -123.50 | -41.00 | -114.50 |
Fiscal Year end for Korro Bio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 24.13 | 21.45 | 39.53 | 12.67 | 11.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | -24.13 | -21.45 | -39.53 | -12.67 | -11.83 |
Non-Operating Income | 2.33 | 1.91 | 1.35 | 1.04 | 1.04 |
Interest Expense | 0.00 | 0.00 | -0.28 | 0.00 | 0.00 |
Pretax Income | -21.80 | -19.54 | -39.21 | -11.62 | -10.79 |
Income Taxes | 0.03 | 0.02 | 0.02 | -0.01 | -0.01 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.83 | -19.56 | -39.23 | -11.61 | -10.79 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.83 | -19.56 | -39.22 | -11.61 | -10.80 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 8.99 | 8.02 | NA | NA | 0.72 |
Diluted EPS Before Non-Recurring Items | -2.43 | -2.44 | NA | NA | -15.00 |
Diluted Net EPS (GAAP) | -2.43 | -2.44 | 4.92 | -15.50 | -15.00 |